WorldQuant Millennium Advisors
SMMT icon

WorldQuant Millennium Advisors’s Summit Therapeutics SMMT Stock Holding History

WorldQuant Millennium Advisors’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.28M Buy
431,028
+372,756
+640% +$6.61M 0.02% 363
2026
Q1 		$1.1M Buy
58,272
+16,538
+40% +$267K ﹤0.01% 498
2025
Q4 		$730K Buy
+41,734
New +$785K ﹤0.01% 508

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

WorldQuant Millennium Advisors's SMMT Position: Q2 2026 in Review

WorldQuant Millennium Advisors increased its Summit Therapeutics (SMMT) stake by 640% in Q2 2026, buying an estimated $6.61M and bringing the position to 431,028 shares worth $6.28M. The position accounts for 0.02% of the portfolio, ranked #363.

WorldQuant Millennium Advisors first reported a position in SMMT in Q4 2025 and has held it in 3 quarters since. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • WorldQuant Millennium Advisors held 431,028 shares of Summit Therapeutics worth $6.28M as of Q2 2026.
  • WorldQuant Millennium Advisors bought 372,756 Summit Therapeutics shares in Q2 2026, an estimated $6.61M.
  • Summit Therapeutics made up 0.02% of WorldQuant Millennium Advisors's portfolio in Q2 2026, its #363 holding.
  • WorldQuant Millennium Advisors first reported a position in Summit Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on WorldQuant Millennium Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.